Uscom hits jackpot with China approval for hypertension monitor

More than 230 million adults in China suffering from hypertension, a modifiable risk factor, will be able to reduce their risk of heart attack now that medtech company Uscom (ASX: UCM) has had the BP+ device approved for sale by Chinese regulators.

Installed on the International Space Station, the BP+ is a patent-protected device that measures 34 parameters of blood pressure (BP) from three separate points in the arteries. Once connected to the BP+ reporter, users are able to assess vascular health where medical professionals can then prescribe appropriate remedies where suitable.

“We are deeply committed to China and the NMPA approval of the BP+ is a significant endorsement for our technology and an incremental financial opportunity for Uscom China’s business as we move from one product to two,” said Uscom Chairman, Associate Professor Rob Phillips.

“The BP+ solution is anticipated to generate significant new revenue as the devices are fed into our growing network of Chinese distributors.”

The approvals process has been a lengthy one for Uscom which first engaged the Chinese National Medical Products Administration (NMPA) 26 months ago.

Hypertension affects 1 in every 3 adults globally and is the leading risk factor for cardiovascular disease and death. However, it is a modifiable disease which can be treated via medication and lifestyle changes where the BP+ device is proven around the world as one of the most precise monitoring devices that can deliver improved outcomes for patients. In China alone, more than 230 million adults suffer from hypertension, of which many are undiagnosed.

Approval of the BP+ continues inroads Uscom is making into China, having previously secured approval for the USCOM 1A monitor, an earlier iteration of the BP+ tech. Additionally, the Company has commenced the approval process for their SpiroSonic series of digital ultrasonic spirometers for diagnosis and treatment of asthma, COPD and post COVID syndrome.

UCM shares responded well to news of the NMPA approval for BP+, opening at $0.175 which represented a 12.9% increase on their previous $0.155 close.